Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514562 | 0.86 | CA2 (0.46) | CA2PKMSTSCA1CA9 | |
| SCHEMBL941191 | 0.84 | PKM (0.58) | CA2PKMCA1CA9CA12 | |
| SCHEMBL15836200 | 0.84 | CMA1 (0.43) | PTK2BMAOAMAOBS100A4 | |
| SCHEMBL2778224 | 0.84 | ACLY (0.51) | CA2PKMCA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL11169517 | 0.82 | PKM (0.57) | CA2PKMCA1CA9CA12 | |
| SCHEMBL11169516 | 0.82 | PTK2B (0.42) | CA2PKMCA1CA9CA12 | |
| SCHEMBL11597913 | 0.82 | PTK2B (0.42) | CA2PTK2BMAOAMAOBS100A4 | |
| SCHEMBL20647086 | 0.81 | KDM4E (0.50) | CA2PKMCA1CA9CA12 | |
| SCHEMBL20647082 | 0.81 | MAPT (0.46) | CA2PKMCA1CA9CA12 | |
| SCHEMBL8075375 | 0.81 | CA1 (0.51) | CA2PKMSTSCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-10-27 | — | — | US | disclosed |
| US-11447460-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-111417622-A | Sulfonamides and compositions thereof for the treatment of conditions associated with N L RP activity | 诺华炎症研究公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-4140713-A | Phenylethanolamine therapeutic agents | ALLEN & HANBURYS LIMITED (GB) | 1979-02-20 | — | — | US | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1337/4885PKM 2463/4885STS 3360/4885 |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 698/4885PKM 2704/4885STS 202/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CA2 698/4885PKM 2704/4885STS 202/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1296/4885PKM 2721/4885STS 3708/4885 |
| US-11447460-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CA2 1336/4885PKM 2860/4885STS 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.